openPR Logo
Press release

Artificial Blood Market

06-19-2017 04:46 PM CET | Health & Medicine

Press release from: Biotechnology Industry Report By CMI

Artificial blood is an artificially developed substitute for red blood cells.  For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors.
Transfusion of red blood cells (RBCs) is a standard and indispensable therapy for anemic conditions. Blood transfusion process has progressed through various developments, including development of acid-citrate-dextrose blood preservation solution, and cloning of ABO gene. However, blood transfusion come with a high risk of infections. Recombinant erythropoietin stimulating agent therapy has been the prominent therapy in cases such as chronic kidney disease, and chronic anemic conditions. Yet in thrombotic and neoplastic complications, blood transfusion is the only option. Hence, RBC production from hematopoietic stem cells has been the focus of regenerative therapy, with major players investing billions of dollars in R&D related to this technique. However, the final product is yet to receive U.S. Food & Drug Administration (FDA) approval.

Request a sample copy of this report@
www.coherentmarketinsights.com/insight/request-sample/11

Artificial Blood Market Development
There has been significant progress made in the global artificial blood market with respect to finding a suitable method to produce blood cells. Scientists have been trying to develop artificial blood from diverse molecules ranging from perfluorocarbons to hemoglobin. With the advent of research in stem cells, researchers began to develop RBCs from stem cells of cord blood. The enrollment for the first clinical trials of stem-cell based red blood cells began in 2009. This study used stem cells from cord blood and adult bone marrow. The study was conducted at the Hematological Laboratory at the University of Paris VI.

A similar research conducted by scientists at the University of Bristol and the UK’s National Health Service (NHS) using stem cells from adult and umbilical cord blood has shown successful results from initial studies. The study is scheduled to enter clinical trials with 20 subjects in 2017. The focus of these trials is to provide special treatment for specific patient groups, rather than act as complete replacement for blood.


Artificial Blood Market Potential
According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New York Blood Center (NYBC), which is the largest cord blood bank globally in terms of units stored, over half of all stem cell transplants in children, in the U.S., use cord blood. A similar statistic has been noted among adults in Japan.

Post the trial in 2017, production is expected to commence in the following 8 to 10 years, thus prolonging the commercialization of product in the artificial blood market.
Artificial Blood Market Future Outlook
Cord blood stem cell transplantation has proved to be a successful therapy in treatment of around 70 diseases. Developing artificial blood can be of great aid to meet the demand-supply gap in blood transfusion, more so considering the fact that finding compatible donors for sickle cell anemia and thalassemia patients is a mammoth task. Development of artificial blood could be the most viable solution to address the unmet needs among these patients. Continued investment in research and development is crucial for ensuring the commercial application of this technology, a very critical factor to contribute towards development of artificial blood market. Being a critical therapy for a severe life condition, the artificial blood market is expected to get a product in a decade or so.

Get More Details about this Report@
www.coherentmarketinsights.com/ongoing-insight/artificial...

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ blog.coherentmarketinsights.com
Connect with us on LinkedIn @ www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Artificial Blood Market here

News-ID: 585493 • Views: 278

More Releases from Biotechnology Industry Report By CMI

The New Research Trial Drives The Shigella Vaccines Market
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence
Flow Cytometry Market to Surpass US$ 7.64 Billion Threshold by 2025
Flow Cytometry – It’s not just for immunologist anymore Flow cytometry is a widely used method for analyzing the expression of cell surface and intracellular molecules. It can also characterize and define different cell types in a heterogeneous cell population. Moreover, flow cytometry also allows simultaneous multi-parameter analysis of single cells. The growth in flow cytometry market is mainly driven by the combination of technological improvements, growing research activities in life
Dental Bone Graft and Substitutes Market to Surpass US$ 911.4 Million Threshold …
Dental Bone Graft and Substitutes Market Insights Dental bone grafts are used as fillers or scaffolds that facilitate bone formation and helps in the wound healing and are suitable for a variety of clinical procedures such as filling of sockets, preservation of ridge volume (also referred to as ridge preservation), and osteogenesis i.e., the formation of new bones. Dental bone grafts are bioresorbable and are not reactive to antigen-antibody. Bone grafts
Dental Bone Graft and Substitutes Market to Surpass US$ 911.4 Million Threshold …
Dental Bone Graft and Substitutes Market Insights Dental bone grafts are used as fillers or scaffolds that facilitate bone formation and helps in the wound healing and are suitable for a variety of clinical procedures such as filling of sockets, preservation of ridge volume (also referred to as ridge preservation), and osteogenesis i.e., the formation of new bones. Dental bone grafts are bioresorbable and are not reactive to antigen-antibody. Bone grafts

All 5 Releases


More Releases for Blood

Blood Donation Chair
Blood Donation Chair Size: 190 L * 92 W * 135 - 164 H cm Back plate, the angle of inclination of the leg plate. Height adjustment. The adjustments are all electrically controlled and easy to operate. This product comes with three LINAK motors Maximum load capacity: 240 kg Optional: CPR function, weighing function The marketplace was wholly developed by the Jiangsu Medwish Network Technology Co., Ltd., a private corporation based in Jiangsu,
Blood Group Typing Market Banks on Increasing Need for Blood, Blood Products, an …
The global blood group typing market is foreseen to garner a massive demand in the foreseeable future owing to certain factors such as the rising demand for blood and blood products. Nonetheless, the market growth could see an escalation on the back of other factors such as increasing prenatal testing which requires blood grouping, mounting count of road mishaps and trauma incidences requiring blood transfusion, and increasing application in forensic
Artificial Blood Market Development
Artificial Blood Market Potential According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New
Blood Group Typing Market Banks on Increasing Need for Blood, Blood Products, an …
The global blood group typing market is foreseen to garner a massive demand in the foreseeable future owing to certain factors such as the rising demand for blood and blood products. Nonetheless, the market growth could see an escalation on the back of other factors such as increasing prenatal testing which requires blood grouping, mounting count of road mishaps and trauma incidences requiring blood transfusion, and increasing application in forensic
Blood Bank Market 2017
ReportsWeb.com has announced the addition of the “Global Blood Bank Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. Blood Bank industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and
Artificial Blood Market
Artificial blood is an artificially developed substitute for red blood cells. For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors. Transfusion of red blood cells (RBCs) is a standard